Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kay

Showing results (51-60 of 172) with videos related to

Pageof 18
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 1, 2011
The rise of cholesterol testing: how much is unnecessaryHelen Doll, Brian Shine, Jonathan Kay, et al.
Arthritis and Rheumatism|October 2, 2007
Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposureDerrick J Todd, Anna Kagan, Lori B Chibnik, et al.
The New England Journal of Medicine|November 19, 2004
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skinSamuel L Moschella, Jonathan Kay, Bonnie T Mackool, et al.
The New England Journal of Medicine|February 22, 2008
Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skinJonathan Kay, Hasan Bazari, Laura L Avery, et al.
Current Rheumatology Reports|July 15, 2006
Wegener's granulomatosis: is biologic therapy useful?Pasha Sarraf, Jonathan Kay, Robert P Friday, et al.
Arthritis Research & Therapy|December 14, 2019
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritisJeffrey R Curtis, Fenglong Xie, Jonathan Kay, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
ReplyEllen M Gravallese, Jonathan Kay, Jeffrey Duryea, et al.
Seminars in Arthritis and Rheumatism|December 17, 2019
Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic reviewShao-Hsien Liu, Stephen A Morais, Kate L Lapane, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|July 15, 2011
Sensorineural hearing loss following imatinib (Gleevec) administrationHarrison W Lin, Daniel S Roberts, Jonathan Kay, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 29, 2020
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?Daniel F Alvarez, Gertjan Wolbink, Carol Cronenberger, et al.
Pageof 18

Showing results (51-60 of 172) with videos related to

Sort By:
Pageof 18
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 1, 2011
The rise of cholesterol testing: how much is unnecessaryHelen Doll, Brian Shine, Jonathan Kay, et al.
Arthritis and Rheumatism|October 2, 2007
Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposureDerrick J Todd, Anna Kagan, Lori B Chibnik, et al.
The New England Journal of Medicine|November 19, 2004
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skinSamuel L Moschella, Jonathan Kay, Bonnie T Mackool, et al.
The New England Journal of Medicine|February 22, 2008
Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skinJonathan Kay, Hasan Bazari, Laura L Avery, et al.
Current Rheumatology Reports|July 15, 2006
Wegener's granulomatosis: is biologic therapy useful?Pasha Sarraf, Jonathan Kay, Robert P Friday, et al.
Arthritis Research & Therapy|December 14, 2019
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritisJeffrey R Curtis, Fenglong Xie, Jonathan Kay, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
ReplyEllen M Gravallese, Jonathan Kay, Jeffrey Duryea, et al.
Seminars in Arthritis and Rheumatism|December 17, 2019
Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic reviewShao-Hsien Liu, Stephen A Morais, Kate L Lapane, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|July 15, 2011
Sensorineural hearing loss following imatinib (Gleevec) administrationHarrison W Lin, Daniel S Roberts, Jonathan Kay, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 29, 2020
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?Daniel F Alvarez, Gertjan Wolbink, Carol Cronenberger, et al.
Pageof 18